Time Commitment: 3 hours 15 minutes over 6 weeks
Credits Available: 3.25 AMA PRA Category 1 Credit

Multiple myeloma is the second-most-common hematologic malignancy in the United States with approximately 34,470 new cases diagnosed in the United States in 2022. Although multiple myeloma is an incurable disease, numerous active agents are available that, when used in combination, often lead to deep and durable remissions however, the majority of patients with multiple myeloma will eventually relapse. As a result, there has been a dramatic increase in the complexity of care for patients with relapsed/refractory multiple myeloma. To address these gaps and improve the practice of clinicians who treat patients with relapsed/refractory multiple myeloma, this educational intervention will facilitate exchange of information, clinical experience, and practical guidance, while establishing sustainable support networks between the multidisciplinary healthcare team.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: MD, DO, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Joseph Mikhael

HonorHealth Research Institute

I love being a support to the community (both providers and patients) for myeloma - I do do in the Phoenix Valley, but also across the world as the Chief Medical Officer of the International Myeloma Foundation